BD (Becton, Dickinson and Company) announced on January 15, 2025, additional investments in its U.S. manufacturing network to expand capacity for critical medical devices. The company invested over $10 million in 2024 to install new needle and syringe production lines at its plants in Connecticut and Nebraska, with one line already operational.
These new lines are expected to boost BD's capacity of domestically manufactured safety-engineered injection devices by more than 40% and conventional syringes by over 50%, adding hundreds of millions of units annually. The expansion also led to the hiring of more than 215 full-time employees in Nebraska and Connecticut.
BD also plans to invest over $30 million in 2025 to expand manufacturing capacity for IV lines at its plant in Utah, following a $2 million investment in 2024 that increased IV catheter output by over 40 million units annually. These investments underscore BD's commitment to strengthening U.S. healthcare supply chain resilience and meeting ongoing needs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.